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(In 1983, Santos et al. [1] reported the results of
1 patients with acute myelogenous leukemia treated
ith high-dose chemotherapy and an allogeneic bone
arrow transplantation from an HLA antigen–iden-
ical sibling. Transplantations took place between
ctober 7, 1975, and June 7, 1982. Patients were
tudied in 3 different groups. Group I included those
ith refractory disease, group II those in second or
hird remissions or early relapse, and group III those
n ﬁrst remission. The preparative regimen consisted
f busulfan (patients in group I were part of a phase I
tudy receiving 8-20 mg/kg and subsequent patients
eceived 16 mg/kg) orally in 4 doses every 6 hours for
days, and cyclophosphamide (50 mg/kg) for 4 days.
atients received either cyclophosphamide (43 pa-
ients) or cyclosporine (8 patients as part of a phase I
tudy) for graft-versus-host disease (GVHD) prophy-
axis [2]. They received 2.87  0.33  108, 2.86 
.14  108, and 3.05  0.13  108 nucleated marrow
ells for groups I, II, and III, respectively. At the time
f the report, 12 patients were alive and one had
hronic GVHD. Only one patient failed to clear the
igure 1. Survival analysis of 51 patients who underwent transplant
n group II, and 18 in group III.
66eukemia and two relapsed. Causes of death of the
ther 39 patients are detailed in the original report.
ince the initial report, two patients have died: patient
77 of complications of GVHD and patient 195 of
nknown causes 18 years posttransplantation. Both
ere in group III. No more relapses have been ob-
erved.
The 10 surviving patients (7 men and 3 women)
ere aged 13 to 31 years at the time of transplantation
patients 153, 215, 248, 255, 256, 257, 259, 263, 329,
nd 354). Of these, two developed chronic GVHD:
ne in the gut and liver (patient 354) and a second one
n his eyes (patient 153). Both improved over time.
ne patient was lost to follow-up 3 years posttrans-
lantation, but the remaining patients were followed
p between 17 and more than 24 years. In Figure 1,
he survival of the 3 groups can be seen. This is an
pdate of Figure 1 of the original report. There is no
ifference in survival between those who underwent
ransplantation in ﬁrst and subsequent remissions
groups II and III, P  .47).
ith busulfan and cyclophosphamide. Sixteen patients in group I, 17ation w
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Letter to the Editor
BOther groups have modiﬁed this regimen giving a
esser dose of cyclophosphamide [3] although it is
nknown if this approach is either superior or inferior
o that used by Santos et al. [1]. This higher dose
ombination continues to be successfully used in the
herapy of patients undergoing transplantation by our
roup and others [4-6].
In summary, after prolonged follow-up and con-
idering the medical technology available at that time,
llogeneic bone marrow transplantation from an HLA
ntigen–identical sibling with busulfan and cyclophos-
hamide is a viable and curative therapeutic option for
atients with acute myeloid leukemia in remission or
arly relapse.
EFERENCES
. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow trans-
plantation for acute nonlymphocytic leukemia after treatment
with busulfan and cyclophosphamide. N Engl J Med. 1983;309:
1347-1353.
. Tutschka PJ, Beschorner WE, Hess AD, et al. Cyclosporin-A to
prevent graft-versus-host disease: a pilot study in 22 patients
receiving allogeneic marrow transplants. Blood. 1983;61:318-325.. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or B
B & M Tallogeneic bone marrow transplantation compared with intensive
chemotherapy in acute myelogenous leukemia. European
Organization for Research and Treatment of Cancer (EORTC)
and the Gruppo Italiano Malattie Ematologiche Maligne
dell’Adulto (GIMEMA) leukemia cooperative groups. N Engl
J Med. 1995;332:217-223.
. Smith BD, Jones RJ, Lee SM, et al. Autologous bone marrow
transplantation with 4-hydroperoxycyclophosphamide purging
for acute myeloid leukaemia beyond ﬁrst remission: a 10-year
experience. Br J Haematol. 2002;117:907-913.
. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemo-
therapy compared with autologous or allogeneic bone marrow
transplantation in the management of acute myeloid leukemia in
ﬁrst remission. N Engl J Med. 1998;339:1649-1656.
. Kasamon YL, Jones RJ, Diehl LF, et al. Outcomes of autologous
and allogeneic blood or marrow transplantation for mantle cell
lymphoma. Biol Blood Marrow Transplant. 2005;11:39-46.
avier Bolaños-Meade
ric Hartley
ichard J. Jones
eorge W. Santos Bone Marrow Transplant Service
t the Sidney Kimmel Comprehensive Cancer Center
t Johns Hopkins and the Johns Hopkins University
chool of Medicine
altimore, Maryland
367
